Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

8.570 -0.590 (-6.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four. 
Via Benzinga
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Via The Motley Fool
S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings
Via Benzinga
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Recap: uniQure Q4 Earnings
Via Benzinga
Dow Falls 150 Points; Oracle Posts Downbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval. 
Via Investor's Business Daily
Exposures Product Safety
Why Is uniQure Stock Skyrocketing On Tuesday?
uniQure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130. 
Via Benzinga
Exposures Product Safety
QURE Stock Earnings: uniQure Beats EPS, Beats Revenue for Q2 2024
QURE stock results show that uniQure beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Are UniQure Shares Surging Today?
UniQure N.V. (NASDAQ: QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's... 
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
SMART Global Posts Upbeat Results, Joins Aehr Test Systems, MarineMax And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
S&P 500 Edges Higher; Indivior Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 1%; Soligenix Shares Surge
Via Benzinga
Exposures Fossil Fuels
Why UniQure Stock Is Soaring
UniQure shares are trading higher Tuesday after the company announced updated interim data from its ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington's... 
Via Benzinga
MULN Stock Alert: Mullen Announces EV Sale to Spencer Manufacturing
Mullen stock is down on Tuesday even as MULN shareholders learn of a new EV order for subsidiary Bollinger Motors from Spencer Manufacturing. 
Via InvestorPlace
Why Is uniQure (QURE) Stock Up 51% Today?
UniQure stock is up on Tuesday as QURE investors react to positive clinical trial data for its Huntington’s Disease treatment candidate. 
Via InvestorPlace
Dow Falls Over 50 Points; US Small Business Optimism Surges In June
Via Benzinga
Topics Stocks
Exposures US Equities
QURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024
QURE stock results show that uniQure missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure. 
Via Investor's Business Daily
Exposures Product Safety
AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... 
Via Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company... 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Micro-Cap Stocks That Could Be Moonshots
If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning! 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.